CDC Selects OraSure's OraQuick Rapid HIV-1/2 Test for MIRIAD Project
This article was originally published in The Gray Sheet
Executive Summary
OraSure Technologies is hoping that the Centers for Disease Control and Prevention's inclusion of the OraQuick rapid HIV-1/2 test in a maternal AIDS intervention study will raise the product's visibility among U.S. public hospitals.